TransMedics Group, Inc. research snapshot
TMDX AI stock analysis currently reads TransMedics Group as a pioneering medical technology company in organ transplant perfusion with a proprietary Organ Care System platform, growing procedure volumes, and a path to scale profitability. The analysis is not a certain price prediction. At the July 9, 2026 verified close of $72.19, market capitalization was approximately $2.50 billion, and the central question was whether the company can sustain its rapid OCS procedure adoption growth, expand its heart and lung programs alongside liver, improve operating leverage, and navigate competitive threats from cold storage alternatives and emerging perfusion systems. This is informational research and not investment advice.
Current price
$72.19
Market cap
$2.50 billion
AI score
60 / 100
Rating
Strong technology platform, execution risk reflected in price
Trend status
Sharp downtrend from 52-week high, stabilizing near support
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | TransMedics sells a proprietary organ perfusion system (OCS) and associated logistics services to transplant hospitals. Revenue is recurring per-procedure with consumables and service contracts. | Medium-high |
| Moat | The moat rests on FDA-approved OCS technology, clinical data portfolio, regulatory barriers, and first-mover scale in national OCS logistics. Competing perfusion systems exist (OrganOx, XVIVO) but OCS has the broadest platform across heart, lung, and liver. | Medium |
| Management | Founder-CEO Waleed Hassanein holds significant skin in the game and deep domain expertise. The concern is key-person dependency and whether the management team can scale operations while maintaining clinical quality and financial discipline. | Medium |
| Financial trend | TTM revenue of $635.89 million grew strongly YoY, with net income of $171.92 million. Profit margin of 27% is healthy, but debt-to-equity of 175% reflects significant leverage from growth investment. | High |
| Valuation | At 16.1x TTM earnings the stock looks inexpensive, but 35.7x forward earnings and 4.4x sales reflect high expectations for continued hypergrowth. EV/EBITDA of 20.3x is not cheap for a medtech company facing deceleration risk. | Medium |
| Technical trend | TMDX is in a deep downtrend from its $156 high, losing over 50% in the past six months. It found support near $60 and is trying to base. Momentum is bearish with declining moving averages. | Medium-high |
| Risk level | Elevated. Key risks are single-platform concentration, FDA regulatory changes, competitive perfusion systems (OrganOx, Paragonix, XVIVO), hospital adoption cycle, dilution risk, short seller campaigns, and high debt leverage. | Medium-high |
| AI confidence | High confidence on financial data and market cap math. Lower confidence on long-term competitive moat durability and adoption trajectory. | Medium-high data confidence |
TMDX AI stock forecast
TMDX forecast scenarios are structured around OCS procedure volume growth, operating leverage, and competitive dynamics. These are scenario ranges, not precise predictions.
$110 - $160
OCS heart and lung continue rapid FDA label expansion and hospital adoption, liver OCS gains share against OrganOx, operating margins expand past 30%, and a new FDA or CMS policy tailwind materializes. Analyst upgrades to reflect sustained 30%+ revenue growth.
$70 - $110
Procedure volume grows 20-25% annually, OCS maintains leadership but competitive pressure from Paragonix and OrganOx limits market share gains. Margins stabilize around 25%. The stock trades in line with high-growth medtech peers at 20-25x forward earnings.
$40 - $70
A competitor wins FDA approval for a next-gen perfusion system, OCS procedure growth decelerates below 15%, hospital budget constraints limit adoption, or a dilutive secondary offering depresses equity value. Short seller narratives gain traction.
TMDX AI technical analysis
TMDX price action as of July 2026 shows a broken uptrend with the stock 54% off its 52-week high. The RSI is recovering from oversold territory, and volume patterns suggest accumulation near the $60 support zone. All data as of the July 9, 2026 close.
| Level | Value | Why it matters |
|---|---|---|
| Major support | $60.10 | 52-week low and round-number support. A break below opens risk of $45-50 zone. |
| Resistance 1 | $80 | Psychological resistance and prior breakdown level. First key overhead barrier. |
| Resistance 2 | $95 | 200-day moving average area and prior consolidation zone. |
| Major resistance | $115 - $120 | Pre-breakdown support level and analyst consensus target area. |
| 50-day MA | $85 | Stock trading below the 50-day, a recovery above signals near-term momentum shift. |
| 200-day MA | $105 | Well below the 200-day, indicating a secular bear trend until recaptured. |
| RSI (14) | ~38 | Recovering from oversold but still in bearish territory. Needs to clear 50 for trend change. |
| Average volume | 1.35M shares | Elevated relative to share count, indicating active institutional rotation. |
TMDX AI trading strategy
The TMDX AI trading strategy framework provides trend-following and mean-reversion setups for the current downtrend recovery phase. These are educational frameworks, not personalized advice. Consider combining with Pineify Pine Script tools to implement your own rules.
Wait for a weekly close above $80 with above-average volume. Enter on a pullback to $75-78. Trail stop at 1.5x ATR. Target $95 initially, then $110 on continuation.
Invalidation if price closes below $60. Reduced position size during earnings and FDA news events.
Buy near $62-65 support zone if RSI is below 35. Take partial profit at $75-80. This works best when the stock is basing rather than in free-fall.
Full stop below $58. Avoid this setup during the first 30 minutes of trading and before major FDA announcements.
Consider puts or bearish setups if the stock fails to hold $70 after an earnings miss or secondary offering announcement. Short above $85 only with clear rejection on high volume.
Cover immediately if price regains the 50-day MA. High beta (1.88) means short squeezes can be severe.
Investment research summary
TransMedics sells a platform that keeps donor organs alive and perfused outside the body, extending preservation time and improving transplant outcomes. Hospitals pay per procedure for OCS console use, disposable sets, and logistics services. The business model shifts from one-time capital equipment to recurring consumable and service revenue as installed base grows.
The primary moat is FDA-approved clinical data across heart, lung, and liver indications, which creates a regulatory barrier to entry. Switching costs exist as transplant teams train on OCS protocols. Brand and clinical reputation matter critically in transplant surgery. However, competing perfusion systems (OrganOx metra for liver, XVIVO for lung, Paragonix for cold storage) provide credible alternatives.
If TMDX collapses as an investment, it will likely be because: (1) a next-gen competitor wins FDA approval and takes significant share, (2) hospital budget pressure slows OCS adoption, (3) a short seller campaign reveals accounting or clinical data concerns, or (4) the company needs dilutive capital at a depressed stock price. The most dangerous blind spot is assuming the technology is so good that adoption is inevitable.
Founder-CEO Waleed Hassanein (former Harvard surgeon) has deep clinical credibility and ownership alignment. He founded the company in 1998 and has shepherded it through decades of R&D and FDA approvals. The key question is whether this founder-led team can scale operations, navigate competitive threats, and communicate effectively with public market investors during volatile periods.
Organ transplant is a structural growth field driven by aging populations, rising organ failure rates, and the ongoing organ shortage crisis. The shift from static cold storage to normothermic perfusion represents a genuine technological paradigm shift in transplant medicine. CMS and insurer support for broader organ utilization creates a favorable reimbursement backdrop.
At $72.19, TMDX trades at 16.1x TTM earnings but 35.7x forward earnings, implying the market expects significant earnings growth deceleration. EV/Revenue of 4.46x and EV/EBITDA of 20.3x are not distressed but leave limited room for disappointment. The 52-week decline from $156 has partially re-rated the stock, but the market is still pricing in above-medtech-average growth for years to come.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $72.19 | Yahoo Finance | July 9, 2026 |
| Market capitalization | $2.50 billion | Yahoo Finance (verified via share count) | July 9, 2026 |
| Shares outstanding | 34.48 million | Yahoo Finance / company filings | July 9, 2026 |
| TTM revenue | $635.89 million | Yahoo Finance Financials | July 9, 2026 |
| TTM net income | $171.92 million | Yahoo Finance Financials | July 9, 2026 |
| TTM EPS | $4.48 | Yahoo Finance Statistics | July 9, 2026 |
| PE ratio (TTM) | 16.1x | Yahoo Finance (verified calculation) | July 9, 2026 |
| Forward PE | 35.7x | Yahoo Finance Statistics | July 9, 2026 |
| Price / Sales (TTM) | 4.39x | Yahoo Finance Statistics | July 9, 2026 |
| EV / Revenue | 4.46x | Yahoo Finance Statistics | July 9, 2026 |
| EV / EBITDA | 20.3x | Yahoo Finance Statistics | July 9, 2026 |
| Profit margin | 27.0% | Yahoo Finance (verified calculation) | July 9, 2026 |
| Return on equity | 45.2% | Yahoo Finance Statistics | July 9, 2026 |
| Total cash | $461.74 million | Yahoo Finance Balance Sheet | July 9, 2026 |
| Debt / Equity | 174.8% | Yahoo Finance Statistics | July 9, 2026 |
| Free cash flow (TTM) | $108.82 million | Yahoo Finance Cash Flow | July 9, 2026 |
| 52-week range | $60.10 - $156.00 | Yahoo Finance Statistics | July 9, 2026 |
| Beta (5Y) | 1.88 | Yahoo Finance Statistics | July 9, 2026 |
This TMDX AI stock analysis page is for informational and educational use only. It does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All data, scenarios, technical levels, and trading strategy frameworks are based on publicly available information and analytical models that may contain errors or omissions. Past performance is not indicative of future results. Organ transplant technology investing involves significant risks including FDA regulatory uncertainty, competitive dynamics, and adoption execution. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
